JP2019534861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534861A5 JP2019534861A5 JP2019514780A JP2019514780A JP2019534861A5 JP 2019534861 A5 JP2019534861 A5 JP 2019534861A5 JP 2019514780 A JP2019514780 A JP 2019514780A JP 2019514780 A JP2019514780 A JP 2019514780A JP 2019534861 A5 JP2019534861 A5 JP 2019534861A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 61
- 150000003839 salts Chemical class 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- -1 methoxypropyl Chemical group 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 10
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 6
- 208000014644 Brain disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000005107 Premature Birth Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000006712 (C1-C4) deuteroalkyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 2
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010036590 Premature baby Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000006242 amine protecting group Chemical group 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 208000017004 dementia pugilistica Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000006517 essential tremor Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 2
- 230000002025 microglial effect Effects 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 201000001223 septic arthritis Diseases 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229940122601 Esterase inhibitor Drugs 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 239000002329 esterase inhibitor Substances 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 0 CC(NC(*)(C*C(*)(CN(*)*)C=C)C(*)=O)=O Chemical compound CC(NC(*)(C*C(*)(CN(*)*)C=C)C(*)=O)=O 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 150000002366 halogen compounds Chemical class 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- DOHXJAQSKHNDLH-INIZCTEOSA-N NCCCC[C@@H](C(COc(c(F)ccc1)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(c(F)ccc1)c1F)=O)NC(C1CCCC1)=O DOHXJAQSKHNDLH-INIZCTEOSA-N 0.000 description 1
- OLIMBXKACVCIMM-HNNXBMFYSA-N NCCCC[C@@H](C(COc(c(F)ccc1F)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(c(F)ccc1F)c1F)=O)NC(C1CCCC1)=O OLIMBXKACVCIMM-HNNXBMFYSA-N 0.000 description 1
- NBIIDGAHKKJKHI-HNNXBMFYSA-N NCCCC[C@@H](C(COc(cc(cc1F)F)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(cc(cc1F)F)c1F)=O)NC(C1CCCC1)=O NBIIDGAHKKJKHI-HNNXBMFYSA-N 0.000 description 1
- CJMLKFUQJAPXLR-INIZCTEOSA-N NCCCC[C@@H](C(COc(cccc1)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(cccc1)c1F)=O)NC(C1CCCC1)=O CJMLKFUQJAPXLR-INIZCTEOSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395938P | 2016-09-16 | 2016-09-16 | |
| US62/395,938 | 2016-09-16 | ||
| US201762459456P | 2017-02-15 | 2017-02-15 | |
| US62/459,456 | 2017-02-15 | ||
| PCT/US2017/051912 WO2018053353A1 (en) | 2016-09-16 | 2017-09-15 | Ketone inhibitors of lysine gingipain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534861A JP2019534861A (ja) | 2019-12-05 |
| JP2019534861A5 true JP2019534861A5 (enExample) | 2020-11-05 |
| JP7113815B2 JP7113815B2 (ja) | 2022-08-05 |
Family
ID=61618978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514780A Active JP7113815B2 (ja) | 2016-09-16 | 2017-09-15 | リシンジンジパインのケトン阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10730826B2 (enExample) |
| EP (2) | EP4480541A3 (enExample) |
| JP (1) | JP7113815B2 (enExample) |
| KR (1) | KR102780603B1 (enExample) |
| CN (1) | CN109983012B (enExample) |
| AU (2) | AU2017326466B2 (enExample) |
| CA (1) | CA3036862A1 (enExample) |
| CL (1) | CL2019000687A1 (enExample) |
| CO (1) | CO2019002950A2 (enExample) |
| DK (1) | DK3512846T3 (enExample) |
| ES (1) | ES2992410T3 (enExample) |
| IL (1) | IL265389B1 (enExample) |
| MX (1) | MX2019003087A (enExample) |
| PE (1) | PE20190473A1 (enExample) |
| PH (1) | PH12019500570A1 (enExample) |
| RU (1) | RU2019111188A (enExample) |
| TW (1) | TWI787202B (enExample) |
| WO (1) | WO2018053353A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12318377B2 (en) | 2013-12-20 | 2025-06-03 | Seed Health, Inc. | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| IL265389B1 (en) | 2016-09-16 | 2026-07-01 | Quince Therapeutics Inc | Ketone compounds lysine inhibitors gingerapine, preparations containing them and uses thereof |
| CN110944637A (zh) | 2017-05-10 | 2020-03-31 | 库特克希米公司 | 氨基吡啶化合物及其制备方法和使用方法 |
| CA3120756A1 (en) * | 2018-12-20 | 2020-06-25 | Takeda Pharmaceutical Company Limited | Sulfoxonium ylide derivatives as probes for cysteine protease |
| WO2026116429A1 (ja) * | 2024-11-29 | 2026-06-04 | アニコム ホールディングス株式会社 | 方法及びシステム |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| ZA86746B (en) | 1985-02-04 | 1986-09-24 | Merrell Dow Pharma | Novel peptidase inhibitors |
| US5055451A (en) | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
| JPH01163162A (ja) | 1987-12-18 | 1989-06-27 | Showa Denko Kk | アミノ酸誘導体および酵素阻害剤 |
| US5326692B1 (en) | 1992-05-13 | 1996-04-30 | Molecular Probes Inc | Fluorescent microparticles with controllable enhanced stokes shift |
| US5723218A (en) | 1990-04-16 | 1998-03-03 | Molecular Probes, Inc. | Dipyrrometheneboron difluoride labeled flourescent microparticles |
| US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| WO1993000926A1 (en) | 1991-07-02 | 1993-01-21 | Children's Medical Center Corporation | Treatment of periodontal disease with protease inhibitors |
| US5576424A (en) | 1991-08-23 | 1996-11-19 | Molecular Probes, Inc. | Haloalkyl derivatives of reporter molecules used to analyze metabolic activity in cells |
| SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
| EP0605655B1 (en) | 1991-09-16 | 1997-05-07 | Molecular Probes, Inc. | Dimers of unsymmetrical cyanine dyes |
| US5374623A (en) | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
| US5658751A (en) | 1993-04-13 | 1997-08-19 | Molecular Probes, Inc. | Substituted unsymmetrical cyanine dyes with selected permeability |
| CN1175259A (zh) | 1994-12-22 | 1998-03-04 | 生化制药有限公司 | 低分子量双环凝血酶抑制剂 |
| US5656449A (en) | 1995-03-06 | 1997-08-12 | Molecular Probes, Inc. | Neutral unsymmetrical cyanine dyes |
| CA2215720A1 (en) | 1995-03-24 | 1996-10-03 | Molecumetics, Ltd. | .beta.-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins |
| WO1996030396A1 (en) | 1995-03-24 | 1996-10-03 | Molecumetics Ltd. | β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS |
| GB9510264D0 (en) | 1995-05-22 | 1995-07-19 | Iaf Biochem Int | Low molecular weight bicyclic-urea type thrombin inhibitors |
| US5523308A (en) | 1995-06-07 | 1996-06-04 | Costanzo; Michael J. | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| US6596522B2 (en) | 1997-05-08 | 2003-07-22 | The Regents Of The University Of California | Detection of transmembrane potentials by optical methods |
| US5827860A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| US5798276A (en) | 1995-06-07 | 1998-08-25 | Molecular Probes, Inc. | Reactive derivatives of sulforhodamine 101 with enhanced hydrolytic stability |
| US5827866A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| IL119466A (en) | 1995-11-03 | 2001-08-26 | Akzo Nobel Nv | Thrombin inhibitors, their preparation and pharmaceutical compositions containing them |
| US6004536A (en) | 1995-11-14 | 1999-12-21 | Molecular Probes, Inc. | Lipophilic cyanine dyes with enchanced aqueous solubilty |
| US6162931A (en) | 1996-04-12 | 2000-12-19 | Molecular Probes, Inc. | Fluorinated xanthene derivatives |
| US6005113A (en) | 1996-05-15 | 1999-12-21 | Molecular Probes, Inc. | Long wavelength dyes for infrared tracing |
| US5846737A (en) | 1996-07-26 | 1998-12-08 | Molecular Probes, Inc. | Conjugates of sulforhodamine fluorophores with enhanced fluorescence |
| ES2262184T3 (es) | 1996-08-05 | 2006-11-16 | Myriad Genetics, Inc. | Utilizacion de mimeticos de hojas beta como inhibidores de proteasa y de kinasa o como inhibidores de factores de transcripcion. |
| WO1998009987A1 (en) | 1996-09-06 | 1998-03-12 | Biochem Pharma, Inc. | Lactam inhibitors of thrombin |
| US5696157A (en) | 1996-11-15 | 1997-12-09 | Molecular Probes, Inc. | Sulfonated derivatives of 7-aminocoumarin |
| US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
| WO1999026925A1 (en) | 1997-11-26 | 1999-06-03 | Yoshitomi Pharmaceutical Industries, Ltd. | Tryptase inhibitors comprising heterocyclic amide compounds |
| EP1053246B1 (en) | 1998-02-12 | 2003-01-02 | Molecumetics, Ltd. | Beta-sheet mimetics and methods relating to the use thereof |
| US6323219B1 (en) | 1998-04-02 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for treating immunomediated inflammatory disorders |
| US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| ATE349700T1 (de) | 1998-10-27 | 2007-01-15 | Molecular Probes Inc | Übergangsmetallkomplex-haltige lumineszente proteinfarben |
| BR0007778A (pt) | 1999-01-27 | 2002-06-04 | Ortho Mcneil Pharm Inc | Peptidila cetonas heterocìclicas úteis como inibidores de triptase |
| HK1039110A1 (zh) | 1999-03-15 | 2002-04-12 | Axys Pharmaceuticals, Inc. | 以新颖的合成物及组分作为蛋白酶抑制剂 |
| WO2000064988A1 (en) | 1999-04-23 | 2000-11-02 | Molecular Probes, Inc. | Xanthene dyes and their application as luminescence quenching compounds |
| US6790989B2 (en) | 2000-01-13 | 2004-09-14 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
| OA12323A (en) * | 2000-03-21 | 2006-05-15 | Smithkline Beecham Corp | Protease inhibitors. |
| AU7918501A (en) | 2000-08-04 | 2002-02-18 | Molecular Probes Inc | Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings |
| US6579718B1 (en) | 2000-08-04 | 2003-06-17 | Molecular Probes, Inc. | Carbazolylvinyl dye protein stains |
| EP2325263B1 (en) | 2000-09-29 | 2013-01-23 | Life Technologies Corporation | Modified carbocyanine dyes and their conjugates |
| US6972326B2 (en) | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
| US7205384B2 (en) | 2003-08-05 | 2007-04-17 | Ortho-Mcneil Pharmaceutical Inc. | Process for preparing peptidyl heterocyclic ketone derivatives |
| US7446202B2 (en) | 2003-12-05 | 2008-11-04 | Molecular Probes, Inc. | Cyanine dye compounds |
| EP1799244A4 (en) | 2004-07-23 | 2010-06-09 | Smith Judith | INHIBITORS OF FURINE |
| EP2027143A2 (en) | 2006-05-23 | 2009-02-25 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| EP2262783A2 (en) | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
| CN101942410A (zh) * | 2010-06-13 | 2011-01-12 | 浙江大学 | 牙龈卟啉单胞菌促血凝功能结构域hgp44基因的克隆重组菌及构建方法 |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| EP4218829A3 (en) | 2013-03-15 | 2023-08-16 | The Board of Trustees of the Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
| CZ2014527A3 (cs) | 2014-08-05 | 2016-02-17 | Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. | Způsob detekce aktivní formy analytů ve vzorku a stanovení schopnosti dalších látek vázat se do aktivních míst těchto analytů |
| EP3204352B1 (en) * | 2014-10-06 | 2020-07-01 | Cortexyme, Inc. | Inhibitors of lysine gingipain |
| IL265389B1 (en) | 2016-09-16 | 2026-07-01 | Quince Therapeutics Inc | Ketone compounds lysine inhibitors gingerapine, preparations containing them and uses thereof |
| US10934261B2 (en) | 2016-09-28 | 2021-03-02 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| UA126027C2 (uk) | 2017-02-15 | 2022-08-03 | АрКьюЕкс ФАРМАСЬЮТІКЛС, ІНК. | Макроциклічні антибіотики широкого спектра |
| CN110944637A (zh) | 2017-05-10 | 2020-03-31 | 库特克希米公司 | 氨基吡啶化合物及其制备方法和使用方法 |
-
2017
- 2017-09-15 IL IL265389A patent/IL265389B1/en unknown
- 2017-09-15 WO PCT/US2017/051912 patent/WO2018053353A1/en not_active Ceased
- 2017-09-15 EP EP24187049.2A patent/EP4480541A3/en active Pending
- 2017-09-15 RU RU2019111188A patent/RU2019111188A/ru unknown
- 2017-09-15 JP JP2019514780A patent/JP7113815B2/ja active Active
- 2017-09-15 CN CN201780068518.0A patent/CN109983012B/zh active Active
- 2017-09-15 EP EP17851664.7A patent/EP3512846B1/en active Active
- 2017-09-15 PE PE2019000533A patent/PE20190473A1/es unknown
- 2017-09-15 DK DK17851664.7T patent/DK3512846T3/da active
- 2017-09-15 TW TW106131764A patent/TWI787202B/zh active
- 2017-09-15 AU AU2017326466A patent/AU2017326466B2/en active Active
- 2017-09-15 ES ES17851664T patent/ES2992410T3/es active Active
- 2017-09-15 CA CA3036862A patent/CA3036862A1/en active Pending
- 2017-09-15 KR KR1020197010797A patent/KR102780603B1/ko active Active
- 2017-09-15 MX MX2019003087A patent/MX2019003087A/es unknown
-
2019
- 2019-03-14 US US16/353,786 patent/US10730826B2/en active Active
- 2019-03-15 CL CL2019000687A patent/CL2019000687A1/es unknown
- 2019-03-15 PH PH12019500570A patent/PH12019500570A1/en unknown
- 2019-03-27 CO CONC2019/0002950A patent/CO2019002950A2/es unknown
-
2020
- 2020-06-11 US US16/899,376 patent/US11325884B2/en active Active
-
2022
- 2022-02-11 AU AU2022200927A patent/AU2022200927B2/en active Active
- 2022-05-09 US US17/740,260 patent/US12110263B2/en active Active
-
2024
- 2024-10-03 US US18/905,445 patent/US20250270162A1/en active Pending